Revalasio Starts MS Trial

Revalesio has begun a Phase IIa trial of RNS60 in patients with relapsing-remitting multiple sclerosis (RRMS or MS). The trial will be conducted by neurologist Dr. Roland Martin, head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich.

The study will compare measurements of disease activity and progression in patients with RRMS during six months treatment with RNS60. The open label study will enroll 15 patients and evaluate the use of RNS60 by intravenous administration compared to patient’s pre-treatment disease activity. The main outcome of the study will be the reduction of inflammatory activity in the brain as measured by Gd contrast-enhacing MRI lesions. Additional measures include progression of disability and biomarkers for RNS60 and general inflammation. The study will be conducted at the University Hospital Zurich in Switzerland and at Innsbruck Medical University in Innsbruck, Austria.

RNS60 has been tested in numerous pre-clinical models of MS and has shown the ability to halt disease progression by limiting glial infiltration (inflammation in the brain), protecting myelin and enriching the regulatory T-cell (TREG) populations in animals treated with RNS60.